Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma e Biotech world.Lilly has entered a $1.6 billion deal in the molecular glue space, following the steps of other big pharma players like Novo Nordisk, Pfizer, and Novartis. On the other hand, the FDA, NIH, and CDC are experiencing chaos with canceled meetings and postponed discussions since Donald Trump's return as U.S. president, without a clear reason. In other news, Cassava's stock is on the rise after licensing seizure rights for simufilam, while BridgeBio Oncology is going public through a SPAC deal. Meanwhile, Vertex has decided to sever a partnership for liver gene therapies. Trilink is offering mRNA designs for reliable performance, and Eisai is planning to cut 7% of its US workforce.The role of mRNA in bridging the innovation gap in rare diseases is being discussed, highlighting the importance of industry and AI in fighting misinformation and empowering patients.Thank you for tuning in to Pharma and Biotech daily.